CureGBM is dedicated to pioneering a breakthrough in brain tumour treatment through innovative sonodynamic therapy. Our non-invasive approach gently targets tumours, improving patient outcomes and enhancing their quality of life. Join us in our mission to transform healthcare.
Our Mission: To make Sonodynamic Therapy (SDT) the Third Treatment for Brain Tumours, after surgery and Chemo/Radiotherapy.
What is GBM?
The most common primary brain tumour is Glioblastoma (GBM) which gives an average life expectancy of only 14 months despite current treatment of surgery and chemo/radiotherapy. GBM is a disease without cure.
GBM spreads through the brain making it near impossible to remove surgically and it is made up of different subtypes, some always survive the treatments above and regrow as a RESISTANT tumour.
Early SDT studies have shown more than double the survival benefit of other experimental therapies. Experimental therapies have shown no more than 3-4 months survival benefit, using treatments such as immunotherapy (tumour vaccines), tumour-treating fields, nanoparticle delivery or ultrasound to open the Blood Brain Barrier for novel chemotherapeutics.
SDT targets ALL cancerous cells, regardless of molecular subtype and will localise to pockets of tumour invisible to the surgeon’s microscope during surgery and not seen on MRI performed post-treatment.
This is why we are bringing this treatment to Europe from America, early trial results can be seen here: https://www.youtube.com/watch?v=TD4KaKuCeOk
What is Sonodynamic Therapy (SDT)
Sonodynamic Therapy (SDT) is an innovative, non-invasive treatment designed to target and destroy cancer cells using sound waves. It combines a special drug—called a sonosensitiser—with focused ultrasound to activate a powerful therapeutic effect inside the body.
The sonosensitiser being used in our clinical trial is ALA, which has been safely used by neurosurgeons for 20yrs.
Unlike radiation or chemotherapy, SDT is highly targeted and gentle. It reaches deep into the body, making it ideal for treating tumours that are hard to access. The treatment is silent, painless, and doesn’t require surgery.
SDT is still being refined through research, but early clinical trial results are incredibly promising for people with glioblastoma. It offers a new way to fight cancer with precision, minimal side effects, and maximum impact.’
